Inventor · disambiguated record
Anthony Manning
Also filed as: MANNING ANTHONY · MANNING ANTHONY M
13 granted patents·8 pending applications·94 citations·filing 1997–2023
91Inventor score
Files withMOMENTA PHARMACEUTICALS INC13SIGNAL PHARM LLC3SIGNAL PHARM INC2MANNING ANTHONY M1SIGNAL PHARMACEUTICALS1
Top patents by PatentIndex Score
21 records- 0194US10676526B2FcRn antibodies and methods of use thereofMOMENTA PHARMACEUTICALS INC·Filed 2016·Granted Jun 9, 2020·9 cites·19 claims
- 0289US11352415B2Methods for the treatment of neurodegenerationMOMENTA PHARMACEUTICALS INC·Filed 2019·Granted Jun 7, 2022·4 cites·5 claims
- 0387US11345751B2FcRn antibodies and methods of use thereofMOMENTA PHARMACEUTICALS INC·Filed 2017·Granted May 31, 2022·4 cites·40 claims
- 0485US10464996B2Methods for the treatment of neurodegenerationMOMENTA PHARMACEUTICALS INC·Filed 2014·Granted Nov 5, 2019·7 cites·6 claims
- 0583US11732047B2FcRn antibodies and methods of use thereofMOMENTA PHARMACEUTICALS INC·Filed 2020·Granted Aug 22, 2023·1 cites·26 claims
- 0682US7119114B1Pyrazoloanthrone and derivatives thereof as JNK inhibitors and compositions and methods related theretoSIGNAL PHARM LLC·Filed 2000·Granted Oct 10, 2006·16 cites·19 claims
- 0780US6656713B2Compounds and methods for modulating activation of NF-κBSIGNAL PHARM INC·Filed 2001·Granted Dec 2, 2003·14 cites·7 claims
- 0879US12297256B2Methods for the treatment of neurodegenerationMOMENTA PHARMACEUTICALS INC·Filed 2022·Granted May 13, 2025·0 cites·16 claims
- 0978US2024158508A1FcRn Antibodies and Methods of Use ThereofMOMENTA PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1075US7414120B2Compounds and methods for modulating activation of NF-κBSIGNAL PHARMACEUTICALS·Filed 2007·Granted Aug 19, 2008·2 cites·7 claims
- 1172US5932425ACompositions and methods for modulating cellular NF-κB activationSIGNAL PHARM INC·Filed 1997·Granted Aug 3, 1999·35 cites·7 claims
- 1264US7186503B2Compounds and methods for modulating activation of NF-κBSIGNAL PHARM LLC·Filed 2003·Granted Mar 6, 2007·2 cites·4 claims
- 1364US2023049725A1FcRn Antibodies and Methods of Use ThereofMOMENTA PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 1456US8263326B2Compounds and methods for modulating activation of NF-κBMANNING ANTHONY M·Filed 2008·Granted Sep 11, 2012·0 cites·5 claims
- 1553US7335676B2Methods for treating inflammatory conditions or inhibiting JNKSIGNAL PHARM LLC·Filed 2003·Granted Feb 26, 2008·0 cites·6 claims
- 1648US2022064298A1COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CTLA-4MOMENTA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1748US2021147549A1COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1MOMENTA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 1846US2004072888A1Methods for treating inflammatory conditions or inhibiting JNKFiled 2003·Application pending·0 cites
- 1945US2021269546A1COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38MOMENTA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2044US2025346676A1COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CCR4MOMENTA PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2141US2019048417A1Therapeutic and Diagnostic Methods for Autoimmune Diseases and/or InflammationMOMENTA PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →